Byotrol PLC – Interim Results

Byotrol Plc (AIM: BYOT), the anti-microbial technology company, is pleased to announce today its interim results for the six months ended 30 September 2019.

 

Highlights

 

•              Sales of £2.17m v. £1.12m in H1 2018 (as restated for application of IFRS15)

•              Adjusted operating loss before share based charges (and including cash receivable for R & D tax credits) of £0.51m versus £0.92m in H1 2018

•              Gross cash and cash equivalents of £2.01m at period end, sufficient to complete growth plans

•              All business units and strategic initiatives progressing satisfactorily.

•              Medimark running ahead of previous year

•              Continued confidence in positive EBITDA at year end

 

 

John Langlands, non-executive Chairman of Byotrol commented:

 

“We are pleased with progress in the year to date

 

Trading losses are reducing rapidly and will continue to do so as the formal integration with Medimark concludes at year end.  The team is also working on a number of business development and monetisation opportunities that should improve results for the full year. The board remains confident that the Company is on target to deliver sustainable operating profits.

 

We remain very excited about the business outlook for Byotrol.“